Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
NASDAQ:HALO
Price:
40.3 USD
1.21%
Market Closed
Updated:
May 4, 2024
Halozyme Therapeutics Inc
Cash from Operating Activities
|
Halozyme Therapeutics Inc
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
Cash from Operating Activities
$388.6m
|
CAGR 3-Years
91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Halozyme Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
388.6m
USD
388.6m
USD
Based on the financial report for Dec 31, 2023, Halozyme Therapeutics Inc's Cash from Operating Activities amounts to 388.6m USD.
What is Halozyme Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
91%
91%
Over the last year, the Cash from Operating Activities growth was 62%. The average annual Cash from Operating Activities growth rates for Halozyme Therapeutics Inc have been 91% over the past three years .
You don't have any saved screeners yet
